PLEASANTON, Calif., Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023.
Recent Highlights
"We had another solid quarter of revenue growth driven by Xenium, as we continued to ramp operations and drive exceptional demand with researchers worldwide," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Xenium's incredibly steep adoption curve in just three full quarters of launch has put the platform on a best-in-class trajectory. The extraordinary customer enthusiasm and demand we are seeing for this platform further strengthens our conviction in the spatial opportunity and validates our multi-platform strategy and investment."
Third Quarter 2023 Financial Results
Revenue was $153.6 million for the third quarter of 2023, a 17% increase from $131.1 million for the corresponding prior year period.
Gross margin was 62% for the third quarter of 2023, as compared to 77% for the corresponding prior year period. The decrease in gross margin was primarily due to product mix primarily driven by the strength of Xenium instrument placements.
Operating expenses were $190.3 million for the third quarter of 2023, a 35% increase from $140.7 million for the corresponding prior year period. This increase was driven by $41.4 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year. Other drivers of the increase in operating expenses this quarter include increased personnel expenses, including stock-based compensation.
Operating loss was $94.8 million for the third quarter of 2023, as compared to $40.0 million for the corresponding prior year period. Operating loss includes $41.4 million of in-process research and development expense and $40.2 million of stock-based compensation for the third quarter of 2023, as compared to $33.5 million of stock-based compensation for the corresponding prior year period.
Net loss was $93.0 million for the third quarter of 2023, as compared to a net loss of $41.9 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $356.9 million as of September 30, 2023.
2023 Financial Guidance
10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $610 million to $625 million, representing 18% to 21% growth over full year 2022.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the third quarter 2023 financial results, business developments and outlook after market close on Thursday, November 2, 2023 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum and progress, our expected performance advantages and benefits of using our products and services, customer enthusiasm and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact of adverse geopolitical and macroeconomic events, difficulties selling in APAC, product capabilities and adoption rates, international economic, political, legal, compliance, social and business factors, inflation and supply chain interruptions may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media: This email address is being protected from spambots. You need JavaScript enabled to view it.
10x Genomics, Inc. | |||||||
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Revenue (1) | $ 153,644 | $ 131,072 | $ 434,748 | $ 360,177 | |||
Cost of revenue (2) | 58,115 | 30,377 | 141,217 | 83,559 | |||
Gross profit | 95,529 | 100,695 | 293,531 | 276,618 | |||
Operating expenses: | |||||||
Research and development (2) | 66,507 | 67,290 | 205,065 | 202,053 | |||
In-process research and development | 41,402 | — | 41,402 | — | |||
Selling, general and administrative (2) | 82,415 | 73,401 | 257,205 | 219,413 | |||
Total operating expenses | 190,324 | 140,691 | 503,672 | 421,466 | |||
Loss from operations | (94,795) | (39,996) | (210,141) | (144,848) | |||
Other income (expense): | |||||||
Interest income | 4,300 | 2,025 | 12,269 | 3,832 | |||
Interest expense | (1) | (114) | (25) | (351) | |||
Other expense, net | (1,248) | (1,950) | (4,268) | (4,193) | |||
Total other income (expense) | 3,051 | (39) | 7,976 | (712) | |||
Loss before provision for income taxes | (91,744) | (40,035) | (202,165) | (145,560) | |||
Provision for income taxes | 1,242 | 1,879 | 3,982 | 3,225 | |||
Net loss | $ (92,986) | $ (41,914) | $ (206,147) | $ (148,785) | |||
Net loss per share, basic and diluted | $ (0.79) | $ (0.37) | $ (1.77) | $ (1.31) | |||
Weighted-average shares of common stock used in | 117,728,293 | 114,112,382 | 116,693,008 | 113,555,750 | |||
(1) The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Instruments | |||||||
Chromium | $ 12,231 | $ 14,936 | $ 36,716 | $ 43,309 | |||
Spatial | 22,711 | 5,963 | 48,357 | 6,755 | |||
Total instruments revenue | 34,942 | 20,899 | 85,073 | 50,064 | |||
Consumables | |||||||
Chromium | 100,282 | 97,868 | 302,172 | 280,195 | |||
Spatial | 14,091 | 10,239 | 37,067 | 23,796 | |||
Total consumables revenue | 114,373 | 108,107 | 339,239 | 303,991 | |||
Services | 4,329 | 2,066 | 10,436 | 6,122 | |||
Total revenue | $ 153,644 | $ 131,072 | $ 434,748 | $ 360,177 | |||
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Americas | |||||||
United States | $ 96,094 | $ 75,345 | $ 260,769 | $ 202,159 | |||
Americas (excluding United States) | 2,917 | 2,236 | 8,581 | 5,997 | |||
Total Americas | 99,011 | 77,581 | 269,350 | 208,156 | |||
Europe, Middle East and Africa | 32,019 | 27,927 | 91,687 | 74,067 | |||
Asia-Pacific | |||||||
China¹ | 12,431 | 16,313 | 39,217 | 48,079 | |||
Asia-Pacific (excluding China) | 10,183 | 9,251 | 34,494 | 29,875 | |||
Total Asia-Pacific | 22,614 | 25,564 | 73,711 | 77,954 | |||
Total Revenue | $ 153,644 | $ 131,072 | $ 434,748 | $ 360,177 | |||
1 Includes Hong Kong effective from the first quarter of 2023. Comparative periods have been adjusted for this inclusion. |
(2) Includes stock-based compensation expense as follows:
Three Months Ended | Nine Months Ended | ||||||
(in thousands) | 2023 | 2022 | 2023 | 2022 | |||
Cost of revenue | $ 1,844 | $ 1,281 | $ 5,140 | $ 3,748 | |||
Research and development | 17,856 | 14,476 | 55,196 | 41,346 | |||
Selling, general and administrative | 20,535 | 17,757 | 67,696 | 50,780 | |||
Total stock-based compensation expense | $ 40,235 | $ 33,514 | $ 128,032 | $ 95,874 | |||
10x Genomics, Inc. | |||
September 30, | December 31, | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 311,264 | $ 219,746 | |
Marketable securities | 45,643 | 210,238 | |
Restricted cash | 500 | 2,633 | |
Accounts receivable, net | 103,847 | 104,211 | |
Inventory | 80,917 | 81,629 | |
Prepaid expenses and other current assets | 20,177 | 16,578 | |
Total current assets | 562,348 | 635,035 | |
Property and equipment, net | 285,008 | 289,328 | |
Restricted cash | 2,974 | 4,974 | |
Operating lease right-of-use assets | 69,192 | 69,882 | |
Goodwill | 4,511 | 4,511 | |
Intangible assets, net | 21,833 | 22,858 | |
Other noncurrent assets | 2,674 | 2,392 | |
Total assets | $ 948,540 | $ 1,028,980 | |
Liabilities and stockholders' equity | |||
Current liabilities: | |||
Accounts payable | $ 18,836 | $ 21,599 | |
Accrued compensation and related benefits | 28,477 | 32,675 | |
Accrued expenses and other current liabilities | 36,256 | 59,779 | |
Deferred revenue | 11,143 | 7,867 | |
Operating lease liabilities | 10,005 | 9,037 | |
Total current liabilities | 104,717 | 130,957 | |
Operating lease liabilities, noncurrent | 88,468 | 86,139 | |
Other noncurrent liabilities | 10,139 | 6,141 | |
Total liabilities | 203,324 | 223,237 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Preferred stock | — | — | |
Common stock | 2 | 2 | |
Additional paid-in capital | 1,981,359 | 1,839,397 | |
Accumulated deficit | (1,235,468) | (1,029,321) | |
Accumulated other comprehensive loss | (677) | (4,335) | |
Total stockholders' equity | 745,216 | 805,743 | |
Total liabilities and stockholders' equity | $ 948,540 | $ 1,028,980 | |
| Last Trade: | US$15.00 |
| Daily Change: | -0.08 -0.53 |
| Daily Volume: | 1,779,060 |
| Market Cap: | US$1.600B |
November 07, 2024 October 31, 2024 October 29, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
